U.S. patent application number 17/206781 was filed with the patent office on 2021-11-11 for base composition for tape agent.
This patent application is currently assigned to MEDRX CO., LTD.. The applicant listed for this patent is MEDRX CO., LTD.. Invention is credited to Hidetoshi Hamamoto, Takahiro Tanimoto, Katsuhiro Yamanaka.
Application Number | 20210346311 17/206781 |
Document ID | / |
Family ID | 1000005735902 |
Filed Date | 2021-11-11 |
United States Patent
Application |
20210346311 |
Kind Code |
A1 |
Hamamoto; Hidetoshi ; et
al. |
November 11, 2021 |
Base Composition for Tape Agent
Abstract
The present invention provides a composition for a non-aqueous
patch preparation having an excellent adhesibility which can
sustainedly release a drug. The patch preparation of the present
invention can improve the adhesibility thereof as well as the
release property of a drug by the addition of powder ingredient
(e.g. a filler). As a result, the long-time sustention of the
adhesibility of patch preparations can achieve the improvement of
the transdermal absorbability and the sustained release of a drug.
By the use of a composition for a patch preparation comprising this
powder ingredient, a drug, regardless of the type of a drug is
dissolved in an organic solvent or an ionic liquid to prepare a
drug solution comprising the organic solvent, the drug solution is
incorporated into the non-aqueous patch preparation of the present
invention, and thereby a preparation with the improved
transdermal-absorbability and sustained release can prepared.
Inventors: |
Hamamoto; Hidetoshi;
(Kagawa, JP) ; Yamanaka; Katsuhiro; (Kagawa,
JP) ; Tanimoto; Takahiro; (Kagawa, JP) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
MEDRX CO., LTD. |
Kagawa |
|
JP |
|
|
Assignee: |
MEDRX CO., LTD.
Kagawa
JP
|
Family ID: |
1000005735902 |
Appl. No.: |
17/206781 |
Filed: |
March 19, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16565790 |
Sep 10, 2019 |
|
|
|
17206781 |
|
|
|
|
15974987 |
May 9, 2018 |
|
|
|
16565790 |
|
|
|
|
14917908 |
Mar 9, 2016 |
9980920 |
|
|
PCT/JP2014/073996 |
Sep 10, 2014 |
|
|
|
15974987 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 45/00 20130101;
A61K 38/00 20130101; A61K 9/7053 20130101; A61K 31/485 20130101;
A61K 31/165 20130101 |
International
Class: |
A61K 9/70 20060101
A61K009/70; A61K 45/00 20060101 A61K045/00; A61K 31/165 20060101
A61K031/165; A61K 31/485 20060101 A61K031/485 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 11, 2013 |
JP |
2013-188886 |
Claims
1-12. (canceled)
13. A composition for a non-aqueous patch preparation comprising a
drug, an organic solvent, and a powder which is insoluble both in
the organic solvent and in a lipophilic plaster base material,
wherein the powder for an adhesive layer is contained as shown in
the following inequality: 0.2.times.(the weight of the adhesive
layer).times.(the bulk density of the powder).ltoreq.the amount of
the powder to be added.ltoreq.0.6.times.(the weight of the adhesive
layer).times.(the tap density of the powder).
14. The composition according to claim 13, wherein the powder is at
least one selected from the group consisting of crystalline
cellulose, anhydrous silicic acid, starch, carmellose, carmellose
metal salt, kaolin, agar, carrageenan, pectin, and powdered
sugar.
15. The composition according to claim 13, wherein the powder is a
mixture of powders.
16. The composition according to claim 13, wherein the organic
solvent comprises a fatty acid-based ionic liquid and/or a
salicylic acid-based ionic liquid.
17. The composition according to claim 16, wherein the fatty
acid-based ionic liquid is an equimolar salt of a saturated or
unsaturated fatty acid having 3 to 22 carbon atoms and an
alkanolamine having 6 to 9 carbon atoms.
18. The composition according to claim 16 further comprising a
saturated or unsaturated fatty acid having 10 to 22 carbon
atoms.
19. The composition according to claim 17, wherein the saturated or
unsaturated fatty acid having 3 to 22 carbon atoms is at least one
selected from the group consisting of lactic acid, levulinic acid,
decanoic acid, oleic acid, isostearic acid, and myristic acid.
20. The composition according to claim 17, wherein the alkanolamine
is at least one selected from the group consisting of
triethanolamine, triisopropanolamine, and diisopropanolamine.
21. The composition according to claim 17, wherein the fatty
acid-based ionic liquid and/or the salicylic acid-based ionic
liquid are at least one selected from the group consisting of
triethanolamine lactate, triisopropanolamine lactate,
triethanolamine levulinate, diisopropanolamine levulinate,
triisopropanolamine decanoate, triethanolamine salicylate,
diisopropanolamine oleate, triethanolamine isostearate,
diisopropanolamine isostearate, and diisopropanolamine
myristate.
22. The composition according to claim 13, wherein the lipophilic
plaster base material comprises an elastomeric
styrene-isoprene-styrene block copolymer.
23. The composition according to claim 13, wherein the drug is
selected from a small molecular medicinal compound, a protein
medicine, an antigen peptide, or a nucleic acid derivative.
24. The composition according to claim 13, wherein the organic
solvent is contained as shown in the following inequality: the
.times. .times. amount .times. .times. .times. of .times. .times.
the .times. .times. solvent .times. .times. to .times. .times. be
.times. .times. added .times. ( the .times. .times. volume .times.
.times. of .times. .times. the .times. .times. solvent .times.
.times. to .times. .times. be .times. .times. added ) < the
.times. .times. amount .times. .times. of .times. .times. the
.times. .times. powder .times. .times. to .times. .times. be
.times. .times. added the .times. .times. tap .times. .times.
density .times. .times. of .times. .times. the .times. .times.
powder .times. .times. 1.2 .times. ( the .times. .times. volume
.times. .times. of .times. .times. the .times. .times. powder
.times. .times. to .times. .times. be .times. .times. added )
##EQU00006##
Description
TECHNICAL FIELD
[0001] The present invention relates to a composition for a plaster
base material comprising a filler. Particularly, the present
invention relates to a composition for a plaster base material in a
non-aqueous tape preparation prepared by solvent method.
BACKGROUND ART
[0002] In order to prepare a composition for a patch preparation
comprising a drug, a set of processes of dissolving a drug in a
solvent such as an organic solvent, diluting the drug solution with
a volatile solvent such as toluene and hexane which is easily
evaporated, mixing the solution with an adhesive, extending the
mixture product, and evaporating the volatile solvent to prepare a
composition for a patch preparation (solvent method) have been
typically used. In such case, the organic solvent used therein has
been employed for serving as a transdermal absorption promoter as
well as for dissolving a drug.
[0003] However, when a large volume of an organic solvent is used
for dissolving a drug, the organic solvent can soften an adhesive
layer in a tape preparation. As a result, the adhesibility of the
tape preparation can be decreased, and also a part of an adhesive
used in the adhesive layer can remain on the skin when the tape
preparation is removed from the skin. In order to prevent such
trouble caused by using a large volume of organic solvent, fillers
are added to an adhesive to improve the lowered adhesibility (e.g.
Patent Document 1).
[0004] Recently, some attempts to use a fatty acid-based ionic
liquid as a solution for dissolving a drug or a transdermal
absorption promoter have been made (e.g. Patent Document 2).
However, a plaster base material used in a tape preparation is a
SIS-based lipophilic plaster base material which has less affinity
for a fatty acid based-ionic liquid because a fatty acid
based-ionic liquid is in a salt form with high polarity, and thus
such plaster base material has a tendency to be less miscible with
the ionic liquid. As a result, a drug solution in which a drug is
dissolved mainly in a fatty acid based-ionic liquid has a tendency
to be easily separated from a lipophilic plaster base material.
[0005] Although a variety of means for solving these problems have
been studied until now, drastic means have not been found.
PRIOR ART DOCUMENTS
Patent Documents
[0006] Patent Document 1: JP 07-215850
[0007] Patent Document 2: JP 2009-066457
SUMMARY OF THE INVENTION
Problem to be Solved by the Invention
[0008] An object of the present invention is to provide a novel
lipophilic plaster base material (adhesive layer) prepared by using
a filler that is insoluble both in the adhesive layer and in an
organic solvent, wherein the filler is dispersed, and spaces
(voids) are formed between the plaster base material and the filler
or spaces (voids) are formed between the fillers. Furthermore, an
object of the present invention is to provide a plaster base
material (adhesive layer) for a non-aqueous tape preparation which
retains a drug solution comprising an active pharmaceutical
ingredient in the spaces (voids) formed by the fillers, and thereby
improves the adhesibility of the tape preparation and the release
property of the drug.
Means for Solving the Problems
[0009] The present inventors have found that by the addition of a
filler (powder) to a non-aqueous patch preparation (tape
preparation) containing a conventional fatty acid-based ionic
liquid, the sustained-release property of a drug solution can be
produced along with the improvement of the adhesibility of an
adhesive layer (PCT/JP2013/66765). Furthermore, the present
inventors have studied the material quality of the filler (powder)
to be added and the amount thereof as well as a combination of the
fillers and the composition thereof, and thus the following
findings can be produced.
[0010] a) The present inventors have found that, in order to form
spaces (voids) between fillers (powder) for retaining a solvent in
a plaster base material (adhesive layer), it is necessary to add an
approximate amount of the powder on the basis of the weight of the
plaster base material (adhesive layer) as shown in the following
inequality, which can be an index of the bulk density of the
powder.
0.2.times.(the weight of the adhesive layer).times.(the bulk
density of the powder).ltoreq.the amount of the powder to be
added.ltoreq.0.6.times.(the weight of the adhesive
layer).times.(the tap density of the powder)
[0011] b) One or more types of powders can be used for forming the
spaces (voids) between the fillers (powder). When two or more types
of the powders are combined, it is preferable to use a mixture of
powder having a large particle size and powder having a small
particle size. The present inventors have found that the preferred
amount of the powder having a large particle size (a small bulk
density) is 20 to 30%.
[0012] c) The spaces (voids) between the fillers (powder) denote
the volume which can retain a solvent therein. When the practical
volume of the solvent exceeds the approximate amount (volume)
thereof as shown in the following inequality, the solvent exudes
onto the surface of an adhesive layer in a tape preparation, and
then the adhesibility of the tape preparation can be decreased.
the .times. .times. amount .times. .times. .times. of .times.
.times. the .times. .times. solvent .times. .times. to .times.
.times. be .times. .times. added .times. ( the .times. .times.
volume .times. .times. of .times. .times. the .times. .times.
solvent .times. .times. to .times. .times. be .times. .times. added
) < the .times. .times. amount .times. .times. of .times.
.times. the .times. .times. powder .times. .times. to .times.
.times. be .times. .times. added the .times. .times. tap .times.
.times. density .times. .times. of .times. .times. the .times.
.times. powder .times. .times. 1.2 .times. ( the .times. .times.
volume .times. .times. of .times. .times. the .times. .times.
powder .times. .times. to .times. .times. be .times. .times. added
) ##EQU00001##
[0013] d) By making the composition suited as mentioned above,
various non-aqueous tape preparations containing powder can be
prepared, which can control two specific properties of the
immediate-release and sustained-release properties of a drug as
shown in FIG. 13, and thus preparations having the desired release
property can be prepared.
[0014] The present inventors have found that even when an ionic
liquid or a mixture of an ionic liquid and an organic solvent is
used in a tape preparation, a drug solution can be retained in
spaces between powder or in spaces between powder and plaster base
by adding a lipophilic plaster base and a powder which is insoluble
both in an ionic liquid and in an organic solvent to a conventional
tape preparation, and thereby, to prevent the drug solution from
being released from the plaster base. As a result, the present
inventors have found that the drug solution does not uselessly
exude onto the surface of the tape preparation, and thus the
adhesibility of the tape preparation and the release property of
the drug can be improved. In addition, the present inventors have
found that even when an ionic liquid is encompassed into a
lipophilic plaster base material (adhesive layer) as droplets, the
drug solution can be released onto the surface of the plaster base
via the spaces between the powder or the spaces between the powder
and the plaster base which are formed by the addition of the
powder, and thus the release property of the drug can be
improved.
[0015] The present inventors have completed the present invention
on the basis of the above findings.
[0016] The subject matters of the present invention are as
follows.
(1) A composition for a non-aqueous patch preparation comprising a
drug, an organic solvent, and a powder which is insoluble both in
the organic solvent and in a lipophilic plaster base material,
wherein the powder for an adhesive layer is contained as shown in
the following inequality:
0.2.times.(the weight of the adhesive layer).times.(the bulk
density of the powder).ltoreq.the amount of the powder to be
added.ltoreq.0.6.times.(the weight of the adhesive
layer).times.(the tap density of the powder).
(2) The composition according to the above item (1), wherein the
powder is at least one selected from the group consisting of
crystalline cellulose, anhydrous silicic acid, starch, carmellose,
carmellose metal salt, kaolin, agar, carrageenan, pectin, and
powdered sugar. (3) The composition according to the above item (1)
or (2), wherein the powder is a mixture of powders. (4) The
composition according to the above item (3), wherein the mixture
comprises 20 to 30 w/w % of anhydrous silicic acid. (5) The
composition according to any one of the above items (1) to (4),
wherein the organic solvent comprises a fatty acid-based ionic
liquid and/or a salicylic acid-based ionic liquid. (6) The
composition according to the above item (5), wherein the fatty
acid-based ionic liquid is an equimolar salt of a saturated or
unsaturated fatty acid having 3 to 22 carbon atoms and an
alkanolamine having 6 to 9 carbon atoms. (7) The composition
according to the above item (5) or (6) further comprising a
saturated or unsaturated fatty acid having 10 to 22 carbon atoms.
(8) The composition according to the above item (7), wherein the
saturated or unsaturated fatty acid having 3 to 22 carbon atoms is
at least one selected from the group consisting of lactic acid,
levulinic acid, decanoic acid, oleic acid, isostearic acid, and
myristic acid. (9) The composition according to the above item (5),
wherein the alkanolamine is at least one selected from the group
consisting of triethanolamine, triisopropanolamine, and
diisopropanolamine. (10) The composition according to the above
item (5), wherein the fatty acid-based ionic liquid and/or the
salicylic acid-based ionic liquid are at least one selected from
the group consisting of triethanolamine lactate,
triisopropanolamine lactate, triethanolamine levulinate,
diisopropanolamine levulinate, triisopropanolamine decanoate,
triethanolamine salicylate, diisopropanolamine oleate,
triethanolamine isostearate, diisopropanolamine isostearate, and
diisopropanolamine myristate. (11) The composition according to any
one of the above items (1) to (10), wherein the lipophilic plaster
base material comprises an elastomeric styrene-isoprene-styrene
block copolymer. (12) The composition according to any one of the
above items (1) to (11), wherein the drug is selected from a small
molecular medicinal compound, a protein medicine, an antigen
peptide, or a nucleic acid derivative. (13) The composition
according to any one of the above items (1) to (12), wherein the
organic solvent is contained as shown in the following
inequality:
the .times. .times. amount .times. .times. .times. of .times.
.times. the .times. .times. solvent .times. .times. to .times.
.times. be .times. .times. added .times. ( the .times. .times.
volume .times. .times. of .times. .times. the .times. .times.
solvent .times. .times. to .times. .times. be .times. .times. added
) < the .times. .times. amount .times. .times. of .times.
.times. the .times. .times. powder .times. .times. to .times.
.times. be .times. .times. added the .times. .times. tap .times.
.times. density .times. .times. of .times. .times. the .times.
.times. powder .times. .times. 1.2 .times. ( the .times. .times.
volume .times. .times. of .times. .times. the .times. .times.
powder .times. .times. to .times. .times. be .times. .times. added
) ##EQU00002##
(14) The composition according to any one of the above items (1) to
(13) further comprising a diester and/or a triester. (15) The
composition according to any one of the above items (1) to (14)
wherein the diester is at least one selected from the group
consisting of diethyl sebacate, diisopropyl adipate, and diisobutyl
adipate, and the triester is at least one selected from the group
consisting of medium-chain triglyceride and triacetin.
Effects of the Invention
[0017] The composition for a non-aqueous patch preparation of the
present invention relates to a non-aqueous patch preparation (tape
preparation) comprising a drug solution in which a drug is
dissolved in an organic solvent (mainly comprising an fatty
acid-based ionic liquid), a lipophilic plaster base material, and a
powder. By the addition of powder, the drug solution with high
polarity can be retained in the spaces between the powder formed in
the lipophilic plaster base material to avoid releasing the drug
solution from the lipophilic plaster base material and exuding onto
the surface of the plaster base. As a result, the deterioration in
the adhesibility of the tape preparation can be prevented. In
addition, the release property and utilization rate of a drug can
be improved because the routes for releasing the drug solution out
of the plaster base are secured with said spaces.
[0018] As described above, the decrease in the adhesibility of a
tape preparation caused by the use of an organic solvent with high
polarity for dissolving a drug (mainly comprising an fatty
acid-based ionic liquid), which has been a problem in conventional
tape preparations, can be improved by using powder in a tape
preparation, and also the release property and utilization rate of
a drug can be greatly improved. Thus, such long-time sustention of
the adhesibility of tape preparations can achieve the improvement
of the transdermal absorbability and the sustained release of a
drug.
[0019] Also, the adhesibility of the lipophilic plaster base
material to a backing support body (a backing) can be enhanced by
the addition of a diester and/or a triester to the organic solvent,
and thus the backing support body is not removed from the plaster
base material in the tape preparation.
BRIEF DESCRIPTION OF THE DRAWINGS
[0020] FIG. 1 is a conceptual diagram showing a cross-section of
the plaster base in the non-aqueous patch preparation (tape
preparation) of the present invention. FIG. 1 shows that the powder
is dispersed into the lipophilic plaster base material (oil-soluble
plaster base), and the drug solution is retained in the spaces
between the powder or in the spaces between the powder and the
plaster base. Furthermore, FIG. 1 shows that quite-narrow channels
for releasing the drug solution from the inside of the plaster base
onto the surface thereof are formed by connecting these spaces to
each other. The parts in which the powder is present on the surface
of the plaster base cause the exudation of the drug solution from
the spaces around the powder, whereas the parts in which the powder
is not present on the surface of the plaster base cause less
exudation or less release of the drug solution. As a result, the
deterioration of the adhesibility of the patch preparation is
prevented as a whole. FIG. 1 also shows the above.
[0021] In FIG. 2, the blue pigment (brilliant blue FCF) was
dissolved in the solution of triethanolamine levulinate in macrogol
400 (weight ratio of 6:14), light silicic acid as the powder was
added thereto, the solution was mixed with the lipophilic plaster
base material, and then the mixture product was extended to prepare
the tape preparation following the conventional solvent method. The
tape preparation was cut into 3.times.3 cm, dipped into a beaker
containing 8 mL of purified water, and then incubated at 32.degree.
C. for 6 hours. The emission amount of the blue pigment from the
sample was measured by the absorption spectrum measurement method
at a wavelength of 630 nm. FIG. 2 is a diagram showing the
correlation between the emission amount of the blue pigment and the
volume ratio of the powder to the plaster base material (the volume
of the powder/the volume of the lipophilic plaster base material).
The volume of the powder was calculated based on the bulk density
thereof.
[0022] FIG. 3 is a diagram showing the correlation between the
emission amount of the blue pigment and the volume ratio of the
powder to the plaster base material in a similar measurement method
to that of FIG. 2, except that crystalline cellulose is used as the
powder.
[0023] FIG. 4 is a diagram showing the correlation between the
emission amount of the blue pigment and the volume ratio of the
powder to the plaster base material in a similar measurement method
to that of FIG. 2, except that corn starch is used as the
powder.
[0024] FIG. 5 is a diagram showing the same correlation as that of
FIG. 2, but the volume ratio of the powder to the plaster base
material is calculated based on the tap density thereof.
[0025] FIG. 6 is a diagram showing the same correlation as that of
FIG. 3, but the volume ratio of the powder to the plaster base
material is calculated based on the tap density thereof.
[0026] FIG. 7 is a diagram showing the same data as that of FIG. 2
in which the horizontal axis represents the amount of the powder in
the adhesive layer of the preparation. FIG. 7 shows that the amount
of light silicic acid is preferably 1 to 5 w/w %, and more
preferably 2.5 to 5 w/w %.
[0027] FIG. 8 is a diagram showing the same data as that of FIG. 3
in which the horizontal axis represents the amount of the powder in
the adhesive layer of the preparation. FIG. 8 shows that the amount
of crystalline cellulose is preferably 2.5 to 18 w/w %, and more
preferably 5 to 15 w/w %.
[0028] FIG. 9 is a diagram showing the same data as that of FIG. 4
in which the horizontal axis represents the amount of the powder in
the adhesive layer of the preparation. FIG. 9 shows that the amount
of corn starch is preferably 20 to 42 w/w %, and more preferably 29
to 42 w/w %.
[0029] FIG. 10 is a diagram showing that when two types of powders
having different particle sizes are combined and the volume of
powder having a larger particle size accounts for about 70% of the
total, the volume of the mixture of the powders becomes the
smallest. FIG. 10 is described in Kimio KAWAKITA et al., Bulletin
of the Faculty of Engineering, Hosei University 2, pages 47-53.
[0030] FIG. 11 is a diagram showing in vivo blood level change of
the drug in mice produced by the use of the tape preparation
containing powders (Test No. A244). FIG. 11 shows that the tape
preparation containing the powders has the sustained-release
property of the drug.
[0031] FIG. 12 is a diagram showing the change in the drug blood
level in mice produced by the use of the tape preparation with no
powder (Test No. A068). FIG. 12 shows that the drug blood level
reaches a peak two hours after the preparation was applied to the
skin, and then is rapidly decreased. FIG. 12 shows the change in
the drug blood level which is greatly different from that of FIG.
11.
[0032] FIG. 13 is a diagram showing that the change in drug the
blood level over time as shown in FIG. 11, which is composed of
biphasic properties of the immediate-release and sustained-release
properties of the drug.
[0033] FIG. 14 is a conceptual diagram showing the imbalance of the
powder in the adhesive layer which is presumed to produce biphasic
behaviors as shown in FIG. 13. The result means the presence of the
region forming the spaces (voids) in which the powder is
collectively combined in the adhesive layer and the region in which
the powder is relatively empty in the adhesive layer, that is, the
region in which the spaces (voids) are not sufficiently formed.
[0034] FIG. 15 is a diagram showing the change in the drug blood
level over time in the rat produced by the use of the preparation
of Test No. N423. The sample of the present invention mainly
produces the immediate-release property of the drug.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0035] The term "drug" in the present invention denotes a drug for
medical use selected from a small molecular medicinal compound, a
protein medicine, an antigen peptide, or a nucleic acid derivative.
Many of the drugs used herein have hydrophilic residue(s) as a main
substituent (or drugs in a salt form thereof). Thus, such drugs are
less soluble in a lipophilic plaster base material. For such
unfavorable insolubility, an ionic liquid with high polarity is
used to dissolve the drug, and the solution of the drug in the
ionic liquid is used as a drug solution. Among the drugs of the
present invention, for example, a small molecular medicinal
compound denotes a drug having an acidity ("acidic drug") or a drug
having a basicity ("basic drug").
[0036] The term "acidic drug" herein denotes a drug which has a
carboxylic acid as a functional group and has an acidity as a whole
of the compound. Examples of the acidic drug include non-steroid
anti-inflammatory drugs (NSAIDs) such as indomethacin, ketoprofen,
ibuprofen, flurbiprofen, diclofenac, etodolac, and loxoprofen;
anti-allergic drugs such as tranilast, cromoglicic acid, and
pemirolast; sedative hypnotic drugs or anti-anxiety drugs such as
amobarbital, secobarbital, and phenobarbital; and muscle relaxant
drugs such as dantrolene, and mivacurium. Preferred examples of the
acidic drug include indomethacin, flurbiprofen, ketoprofen,
etodolac, ibuprofen, loxoprofen, and diclofenac.
[0037] The term "basic drug" herein denotes a drug which has a
primary, secondary, or tertiary amine structure as a functional
group and has a basicity as a whole of the compound. Examples of
the basic drug include topical anesthetic drugs such as lidocaine,
dibucaine, bupivacaine, procaine, mepivacaine, bupivacaine, and
tetracaine; anti-histamine drugs such as diphenhydramine; analgesic
drugs such as tramadol; anti-spasmodic drugs such as eperisone;
muscle relaxant drugs such as tolperisone; antitussive drugs such
as dextromethorphan; acetylcholine decomposition inhibitors such as
donepezil; and opioid analgesic drugs such as morphine, codeine,
naloxone, fentanyl, and oxycodone. Preferred examples of the basic
drug include lidocaine, tolperisone, bupivacaine, eperisone,
tramadol, morphine, and donepezil.
[0038] The term "protein medicine" herein denotes a protein for
medical use. Examples of the protein medicine include various
recombinant proteins and modified proteins which are relatively
small molecules. Examples of various recombinant proteins and
modified proteins include insulin, human growth hormone, elcatonin,
calcitonin, EGF, VEGF, and GLP-1.
[0039] The term "antigen peptide" herein denotes an antigenic
fragment derived from a foreign microbe or a tumor cell which is
used for stimulating immunity. Examples of the antigen peptide
include WT-1, and human papillomavirus.
[0040] The term "nucleic derivative" herein denotes a general term
for DNA and RNA which are used as a medicinal ingredient. The DNA
used herein is not especially limited as long as it is DNA for gene
therapy. Examples of the nucleic derivative include DNA vaccine,
antisense, ribozyme, aptamer, and siRNA.
[0041] The term "fatty acid-based ionic liquid" in the present
invention denotes a Bronsted salt prepared from a fatty acid having
3 to 22 carbon atoms and a alkanolamine compound having 6 to 9
carbon atoms, which is in a viscous liquid form at ambient
temperature.
[0042] The term "salicylic acid-based ionic liquid" in the present
invention denotes a Bronsted salt prepared from salicylic acid and
an alkanolamine compound having 6 to 9 carbon atoms, which is in a
viscous liquid form at ambient temperature.
[0043] Preferably, in order to enhance the skin permeability of a
drug, the ionic liquid used in a drug solution is in the state that
the drug solubility of the drug solution is close to saturation.
Thus, the drug solubility of the drug solution can be controlled
through the addition of one or more saturated or unsaturated fatty
acids having 3 to 22 carbon atoms or a combination of various fatty
acid-based ionic liquids.
[0044] The "fatty acid-based ionic liquid and/or salicylic
acid-based ionic liquid" in the present invention include an
equilibrium mixture of each equimolar amount of an organic
carboxylic acid and an amine compound, besides a Bronsted salt.
Preferred examples of the ionic liquid include triethanolamine
lactate, triisopropanolamine lactate, triethanolamine salicylate,
triisopropanolamine salicylate, triisopropanolamine decanoate,
triethanolamine decanoate, diisopropanolamine decanoate,
diisopropanolamine oleate, triethanolamine isostearate,
diisopropanolamine isostearate, and a mixture thereof.
[0045] The term "drug solution" in the present invention denotes a
solution in which a drug is dissolved in an organic solvent. Also,
the drug solution denotes a solution further comprising an ionic
liquid as a solubilizing agent for the drug or a transdermal
absorption accelerator. The drug solution of the present invention
typically comprises an ionic liquid with high drug solubility.
Also, the organic solvent used herein is required to be miscible
with the ionic liquid. Thus, a polar organic solvent can be
typically used. For example, alcohols such as propylene glycol
and/or esters such as diethyl sebacate and isopropyl myristate can
be used.
[0046] The term "powder" in the present invention denotes a solid
powdered reagent which is insoluble and immiscible both in a drug
solution and in a lipophilic plaster base material (oil-soluble
plaster base material). Specifically, the powder is a solid
powdered reagent which is insoluble in a solvent such as an organic
solvent in the drug solution even though the powder swells due to
the absorption of the solvent. Examples of the powder include a
solid powdered reagent (filler) used in a plaster base in a patch
preparation such as anhydrous silicic acid, crystalline cellulose,
zinc oxide, titanium oxide, kaolin, and calcium carbonate.
Furthermore, examples of the powder include flour, starch powder
such as corn starch, carmellose, carmellose metal salt, agar,
carrageenan, pectin, powdered sugar, polyethylene powder, and
polystyrene sulfonate. Preferred examples of the powder include
crystalline cellulose, anhydrous silicic acid, starch, carmellose,
and carmellose metal salt. The adhesibility of the patch
preparation can be improved with increasing the amount of the
powder of the present invention. Whereas, when the powder is
excessive in amount, the patch preparation becomes hard, and the
adhesibility of the patch preparation is deteriorated. Thus, in
order to form spaces (voids) between the powder for retaining a
solvent in a plaster base material (adhesive layer), it is
necessary to add the preferred amount of the powder on the basis of
the weight of the plaster base material (adhesive layer) as shown
in the following inequality, which can be an index of the bulk
density of the powder.
0.2.times.(the weight of the adhesive layer).times.(the bulk
density of the powder).ltoreq.the amount of the powder to be
added.ltoreq.0.6.times.(the weight of the adhesive
layer).times.(the tap density of the powder).
[0047] In addition, one or more types of powders can be used for
forming the spaces (voids) between the powders. When two or more
types of the powders are combined, it is preferable to use a
mixture of powder having a large particle size and powder having a
small particle size. In such case, it is preferable that the amount
of the powder having a large particle size (i.e., having a small
bulk density) is 20 to 30%.
[0048] Also, the spaces (voids) between the powder denote the
volume which can retain a solvent (drug solution) in a plaster base
material (adhesive layer). The volume is shown in the following
inequality. When the practical amount of an organic solvent to be
added exceeds the volume as shown below, the solvent (drug
solution) exudes onto the surface of the adhesive layer, and then
the adhesibility of the preparation can be decreased.
the .times. .times. amount .times. .times. .times. of .times.
.times. the .times. .times. solvent .times. .times. to .times.
.times. be .times. .times. added .times. ( the .times. .times.
volume .times. .times. of .times. .times. the .times. .times.
solvent .times. .times. to .times. .times. be .times. .times. added
) < the .times. .times. amount .times. .times. of .times.
.times. the .times. .times. powder .times. .times. to .times.
.times. be .times. .times. added the .times. .times. tap .times.
.times. density .times. .times. of .times. .times. the .times.
.times. powder .times. .times. 1.2 .times. ( the .times. .times.
volume .times. .times. of .times. .times. the .times. .times.
powder .times. .times. to .times. .times. be .times. .times. added
) ##EQU00003##
[0049] Thus, the immediate-release and sustained-release properties
of a drug in a non-aqueous tape preparation containing powder can
vary depending on the changes in the amount and composition of the
powder. For example, preparations having a desired release property
can be prepared by controlling two specific properties of the
immediate-release and sustained-release properties of a drug as
shown in FIG. 13.
[0050] In order to control the immediate-release and
sustained-release properties of a drug, the spaces to be formed can
be properly controlled by combining various powders having
different bulk densities. For example, a combination of 20 to 30
w/w % of anhydrous silicic acid having a small bulk density, and
crystalline cellulose or corn starch having a large bulk density
may be used as a mixture of powders.
[0051] The term "powder which is insoluble both in the drug
solution and in the lipophilic plaster base material" in the
present invention means that a powder is insoluble both in an
organic solvent and an ionic liquid, and insoluble in a lipophilic
plaster base so that the spaces between the powder formed in the
lipophilic plaster base can be retained. The term "insoluble" is
used in the sense of insolubility, and means that 1 mg of powder
cannot be dissolved in 10 g of an organic solvent or a lipophilic
plaster base, according to the definition of solubility in the U.S.
(the U.S. Pharmacopeia National Formulary).
[0052] The term "organic solvent" in the present invention denotes
a solvent that is miscible with an ionic liquid, which is used for
preparing a drug solution in which a drug is dissolved in
combination with the ionic liquid. The organic solvent in the
present invention can be also used as a transdermal absorption
accelerator. Furthermore, the organic solvent can be also used for
dispersing the organic carboxylic acid-based ionic liquid in which
a drug is dissolved into the plaster base. Examples of the organic
solvent in the present invention include alcohols such as ethanol,
propanol, and oleyl alcohol; polyalcohols such as ethylene glycol,
propylene glycol, 1,3-butanediol, polyethylene glycol (macrogol),
and glycerin; and esters such as diethyl sebacate, isopropyl
myristate, propylene carbonate, and diisopropyl adipate. In
addition, the organic solvent includes fatty acids such as lactic
acid, levulinic acid, decanoic acid, oleic acid, myristic acid, and
isostearic acid. These organic solvents may be used in suitable
combination to achieve the above purposes. More preferably,
polyalcohols such as propylene glycol, 1,3-butanediol, polyethylene
glycol, and glycerin can be used in combination with esters such as
diethyl sebacate, isopropyl myristate, propylene carbonate, and
medium-chain triglyceride.
[0053] Among the above organic solvents, the solvent retained in
the spaces (voids) formed by powder is mainly a solvent which is
hard to dissolve an adhesive layer (lipophilic plaster base
material) (e.g. a solvent which is less compatible with the
adhesive layer). Examples of the solvent which is less compatible
with the adhesive layer include an alcohol solvent (e.g. macrogol,
propylene glycol, and polyethylene glycol) and a protic solvent
such as a fatty acid-based ionic liquid and a fatty acid. On the
other hand, an ester solvent (e.g. diethyl sebacate and isopropyl
myristate) is more compatible with the adhesive layer (lipophilic
plaster base material), and thus it has a tendency to be hard to be
retained in the spaces (voids) in the adhesive layer. Thus, in
studying the volume of the solvent retained in the spaces (voids)
formed by the powder to keep the adhesibility of a preparation, the
volume of the solvent which is less compatible with the adhesive
layer should be mainly evaluated.
[0054] The term "lipophilic plaster base material" in the present
invention denotes a plaster base (adhesive) comprising a lipophilic
polymer as a main component. The plaster base is composed of an
elastomer and a lipophilic (hydrophobic) adhesive, in which a drug
solution is dispersed or emulsified into the plaster base. When the
plaster base is composed of an elastomer and a lipophilic
(hydrophobic) adhesive, it can be used as a non-aqueous tape
preparation (plaster). When the plaster base is composed of an
elastomer and a hydrophilic adhesive, it can be used as an aqueous
patch preparation (cataplasm). As described above, the lipophilic
plaster base material is composed of various reagents such as an
elastomer, a tackifier, and a softening filler.
[0055] Examples of the elastomer include synthetic rubbers such as
a styrene-isoprene-styrene copolymer (SIS), a silicon rubber,
polyisobutylene, a polystyrene-butadiene copolymer, and
polyisobutylene; acrylic acid resins such as alkyl acrylate and
alkyl methacrylate; and natural rubbers.
[0056] The tackifier denotes a reagent which can be added into the
elastomer such as a SIS resin to enhance the adhesibility of a
patch preparation to the skin. Examples of the tackifier include a
polyterpene resin, a polyolefin resin (e.g. Plastibase.RTM.), a
polystyrene resin, an aromatic petroleum resin, rosin, and
hydrogenated rosin. Preferred examples of the tackifier include a
polyterpene resin and a polyolefin resin (e.g.
Plastibase.RTM.).
[0057] The softening agent is a reagent which can be added to make
the elastomer such as a SIS resin and the adhesive flexible.
Examples of the softening agent include petroleum-based softening
agents such as polybutene, polyisobutylene, and process oil; fatty
oil-based softening agents such as palm oil and castor oil;
purified lanolin; and liquid paraffin. Preferred examples of the
softening agent include polybutene and liquid paraffin.
[0058] The patch preparation of the present invention may further
comprise additives such as an antioxidant, a surfactant, a
thickening agent, and a surfactant as long as the effects of the
present invention are not prevented. As the suitable additives,
commercially available reagents may be used for any purpose.
[0059] Examples of the antioxidant include organic antioxidants
such as BHT, propyl gallate, and sodium ascorbate; and inorganic
antioxidants such as sodium thiosulfate, sodium bisulfite, sodium
sulfite, and sodium pyrosulfite.
[0060] In addition, a thickening agent such as Carbopol.RTM., an
ultraviolet absorbing agent, and/or powders may be added.
[0061] Examples of the surfactant can include a non-ionic
surfactant, an anionic surfactant, a cationic surfactant, and an
amphoteric surfactant. Examples of the non-ionic surfactant include
sorbitan monolaurate, sorbitan monopalmitate, sorbitan
sesquioleate, glycerin monostearate, decaglyceryl monolaurate,
hexaglycerin polyricinoleate, polyoxyethylene (9) lauryl ether,
polyoxyethylene (2) lauryl ether, polyoxyethylene (4,2) lauryl
ether, polyoxyethylene (5) nonylphenyl ether, polyoxyethylene (7,5)
nonylphenyl ether, polyoxyethylene (10) nonylphenyl ether,
polyoxyethylene (3) octylphenyl ether, polyoxyethylene (10)
octylphenyl ether, polyoxyethylene (10) oylelamine, polyoxy (5)
oleylamine, polyoxy (5) oleic amide, polyoxyethylene (2)
monolaurate, monoglyceride stearate, and polyoxyethylene castor oil
(hydrogenated castor oil).
[0062] Examples of the anionic surfactant include sodium lauryl
sulfate, potassium lauryl sulfate, triethanolamine lauryl sulfate,
sodium cetyl sulfate, sodium lauroyl sarcosinate, sodium
di-2-ethylhexyl sulfosuccinate, sodium polyoxyethylene (10) lauryl
ether phosphate, sodium polyoxyethylene (4) lauryl ether phosphate,
sodium polyoxyethylene (5) cetyl ether phosphate, and sodium
polyoxyethylene (6) oleyl ether phosphate.
[0063] Examples of the cationic surfactant include stearyl
trimethylammonium chloride, distearyl dimethylammonium chloride,
benzalkonium chloride, and stearyl dimethyl benzylammonium
chloride.
[0064] Examples of the amphoteric surfactant include betaine
lauryldimethylaminoacetate and
2-alkyl-N-carboxymethyl-N-hydroxyethyl imidazolinium betaine.
Lauroyl diethanolamide may also be used as the amphoteric
surfactant.
[0065] In addition, a thickening agent such as Carbopol.RTM., an
ultraviolet absorbing agent, and/or powders may be added.
[0066] The term "patch preparation" in the present invention
denotes a non-aqueous patch preparation (tape preparation) which
does not contain water as an essential ingredient. As the plaster
base in the patch preparation of the present invention,
conventional bases, for example, an acrylic acid resin base, or a
base of a SIS resin which contains reagents such as a tackifier and
a softening agent can be used. Preferred examples of the base
include a base in which a SIS resin is used as an elastomer.
[0067] As a method for preparing the patch preparation of the
present invention, similar methods to those of adhesive tapes may
be used. Examples of the method include a solvent-coating method.
The solvent-coating method is a method which comprises preparing a
plaster base composition comprising a drug (drug solution), and
directly coating a backing support body with the composition
followed by drying. Also, a method can be used which comprises once
coating a release paper with the plaster base composition followed
by drying, and then removing the paper followed by contact-pressing
the composition on the paper to the backing.
[0068] The release paper can be used for protecting the adhesive
layer. As examples of the paper, a polyethylene-coated quality
paper, a polyolefin-coated glassine paper, a polyethylene
terephthalate (hereinafter referred to as PET) film, a
polypropylene film or the like, one side of which is treated with
silicon, may be used.
[0069] In addition, an additive having a multiple ester such as a
diester and a triester can be added into the patch preparation of
the present invention. The adhesibility of an additive to a backing
is decreased by mixing a powder with the additive. The present
inventors have studied the problem and found that the additive
having a multiple ester such as a diester and a triester can
enhance the adhesibility of an additive to a backing support body
(backing) in a tape preparation, and thus the removal of the
backing in use can be prevented. Examples of the diester include
diethyl sebacate, diisopropyl adipate, and diisobutyl adipate.
Examples of the triester include medium-chain triglyceride and
triacetin.
EXAMPLES
[0070] Hereinafter, the present invention will be described more
specifically with reference to Examples. However, the present
invention is not intended to be limited to them by any means.
Example 1
Measurement of the Bulk Density and the Tap Density of Filler
(Powder)
(1) Measurement of the Bulk Density of Filler (Powder)
[0071] The bulk density of a powder (g/cm.sup.3) is a ratio of the
mass of the powder sample in an untapped (loose) state and the
volume of the powder including the interparticle void volume. Thus,
the bulk density of a powder depends on the particle density of the
powder and the spatial array of particles within the powder
layer.
a) Method:
[0072] The volume of a powder sample with the known mass added into
a graduated cylinder through a sieve was measured to calculate the
bulk density of the powder. Specifically, a powder was passed
through a sieve with 1.0 mm or more meshes to crush an aggregate
which may be formed during storage. About 100 g of a sample (m) was
weighed with 0.1% accuracy, and the sample was carefully added into
a dry 250 mL graduated cylinder (minimum scale value: 2 mL) without
compaction. The upper surface of the powder layer is carefully
floated without compaction to read the aerated bulk volume (V) of
the powder to minimum scale value. The bulk density of the powder
(g/mL) was calculated according to the formula m/V.
b) Measurement Result:
[0073] The measured results of JP corn starch, light anhydrous
silicic acid (AEROSIL.RTM. 200), and crystalline cellulose
(CEOLUS.RTM.) are shown in Table 1 below.
(2) Measurement of the Tap Density of Filler (Powder)
[0074] The tap density of a powder means the increased bulk density
of the powder after a container containing the powder sample is
mechanically tapped. The tap density of a powder is given by
mechanically tapping a graduated cylinder or container for
measurement containing the powder sample.
a) Method:
[0075] The initial volume or mass of powder is measured, and then a
graduated cylinder or container for measurement containing the
powder is mechanically tapped until the volume or mass shows little
change to read the volume or mass of the tapped powder. The
mechanical tapping is performed by lifting up the graduated
cylinder or container, and then dropping it down a given distance
under its own weight. Specifically, a 250 mL graduated cylinder
(minimum scale value: 2 mL) with a mass of 220.+-.44 g and a device
for dropping down the graduated cylinder from a height of 3.+-.2 mm
at a tapped rate of 250.+-.15 times/min are used.
[0076] In the same manner as the above (1), the bulk volume (V) of
the powder is measured. The powder sample to be measured is tapped
10 times, 500 times, and 1250 times to read the corresponding bulk
volumes V10, V500, and V1250 to the minimum scale value. When the
difference between V500 and V1250 is less than 2 mL, V1250 is used
as the tap volume. When the difference between V500 and V1250
exceeds 2 mL, tapping is repeated in increments of 1250 times for
each time until the difference between succeeding measurements
reaches less than 2 mL. The tap density of a powder (g/cm.sup.3) is
calculated according to the formula m/Vf in which Vf is the final
tap volume of the powder.
b) Measurement Result:
[0077] The measured results of JP corn starch, light anhydrous
silicic acid (AEROSIL.RTM. 200), and crystalline cellulose
(CEOLUS.RTM.) are shown in Table 1 below.
TABLE-US-00001 TABLE 1 Bulk Density Tap Density AEROSIL .RTM. 200
0.04 0.09 (light anhydrous silicic acid) CEOLUS .RTM. 0.14 0.31
(crystalline cellulose) JP corn starch 0.50 0.73
[0078] The above bulk density and tap density of each powder mean
the volume of AEROSIL.RTM., CEOLUS.RTM., or corn starch. For
example, when 1 g of AEROSIL.RTM. 200 is used as the powder
(filler), the powder occupies a volume of 25 cm.sup.3 (calculated
as the bulk density of the powder). Also, corn starch occupies a
volume of 2 cm.sup.3 (calculated as the bulk density of the
powder).
[0079] If each specific gravity of AEROSIL.RTM., CEOLUS.RTM., and
corn starch is in the same range, each volume of the powders denote
the size of spaces (voids) formed by each powder. For example, it
is shown that the spaces (voids) formed by AEROSIL.RTM. or
CEOLUS.RTM. are large in size, whereas the spaces (voids) formed by
corn starch is small in size.
[0080] When an excessive amount of light anhydrous silicic acid or
crystalline cellulose is added to the adhesive layer of a
preparation, the adhesive layer enters spaces (voids) between the
powder, and thus the spaces (voids) show little change. On the
other hand, when an excessive amount of powder forms spaces (voids)
in the adhesive layer of a tape preparation, the tape preparation
becomes hard, and the adhesibility of the tape preparation is
deteriorated. Thus, when powder is added, it is required to
optimize the weight ratio of the powder and the adhesive layer of
the preparation. On the other hand, when powder is small in amount,
little space (void) is formed, and thus the powder cannot
sufficiently exert an effect thereof.
Example 2
Optimization of the Ratio of the Volume of Filler (Powder) and the
Amount of Adhesive Layer (Tape Preparation Base Material)
[0081] The problem for effectively utilizing the spaces (voids)
formed in the tape preparation base material is to determine the
amount of a filler (powder) to be added into the adhesive layer of
the preparation.
[0082] The amounts of the ingredients in the adhesive layer were
maintained at an almost constant rate, and the amount of the powder
to be added was increased. The amount of the powder to be added for
forming spaces (voids) between the powder and releasing the drug
solution via the spaces (voids) was investigated. The volume of the
powder was calculated based on the amount of the powder to be added
using the bulk density of the powder as shown in Example 1, and the
association between the volumes of the powder and the adhesive
layer was evaluated.
[0083] As shown in FIG. 1, the spaces (voids) between the powder
are formed with increasing the amount of the powder to be added. As
a result, a drug retained in the spaces (voids) is released from
the surface of the adhesive layer (lipophilic adhesive plaster
base) to the outside thereof via the spaces (voids). In order to
confirm the release property of a drug (i.e., the spaces (voids)
formed by the powder), by using brilliant blue FCF as an
alternative to the drug, the release property of the pigment from
the surface of the adhesive layer (lipophilic adhesive plaster
base) was evaluated.
(1) Preparation of Adhesive Layer (Lipophilic Adhesive Plaster
Base)
[0084] Each reagent was weighed according to the composition (part
by weight) in Table 2 below, and brilliant blue FCF was dissolved
in the solution of triethanolamine levulinate in macrogol 400
(weight ratio of 6:14) to prepare the drug solution. Following the
conventional solvent method, terpene resin,
styrene-isoprene-styrene copolymer (SIS), butylhydroxytoluene, and
liquid paraffin were dissolved in toluene, and then the macrogol
400 solution (weight ratio 6:14) and light anhydrous silicic acid
(AEROSIL.RTM. 200) were added thereto and mixed. Next, each mixture
was applied on the silicone-coated PET film and dried. After
removal of the toluene, the backing was laminated to prepare the
tape preparations.
(2) Detection of the Release Property of Drug Solution (i.e.,
Spaces (Voids) Formed by Powder)
[0085] The prepared tape preparations were tested on the release
property of brilliant blue FCF from the adhesive layer.
Specifically, the prepared tape preparations were cut into
3.times.3 cm, dipped into a beaker containing 8 mL of purified
water, and then incubated at 32.degree. C. for 6 hours. Next, the
emission of the blue pigment from each tape preparation of the
example was measured by the absorption spectrum measurement method
at a wavelength of 630 nm. The results are also shown in Table 2
below.
TABLE-US-00002 TABLE 2 A1 A2 A3 A4 A5 A6 A7 A8 Drug Solution:
Brilliant blue FCF 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016
Triethanolamine 10 9.96 9.92 9.81 9.73 9.62 9.53 9.42
Levulinate/Macrogol 400 Adhesive: Triethanolamine 10 9.96 9.92 9.81
9.73 9.62 9.53 9.42 Levulinate/Macrogol 400 Terpene Resin 38 37.85
37.70 37.26 36.97 36.54 36.22 35.78 SIS 20 19.92 19.84 19.61 19.46
19.23 19.06 18.83 Liquid Parffin 17 16.93 16.87 16.67 16.54 16.35
16.20 16.01 Butylhydroxytoluene 1 1.00 0.99 0.98 0.97 0.96 0.95
0.94 (Total weight of 96.0 95.6 95.3 94.1 93.4 92.3 91.5 90.4
adhesive layer) Filler (Powder): AEROSIL .RTM. 0 0.37 0.75 1.86 2.6
3.7 4.5 5.6 (Volume) (9.3) (18.6) (46.5) (65) (92.5) (112.5) (140)
Volume ratio of powder to 0 9.7 19.5 49.4 69.6 100.2 123.0 154.9
adhesive layer (%) Preparation Form: good good good good good good
bad bad Emission Amount 0.008 0.019 0.061 0.211 0.211 0.190 0.143
0.219 (Absorbance/Measurement Wavelength 630 nm)
[Note]
[0086] The volume of AEROSIL.RTM. 200 was calculated according to
the weight thereof/the bulk density thereof.
[0087] The "volume ratio of the powder to the adhesive layer" was
calculated according to the specific gravity of the adhesive layer
containing the drug solution defined as 1.
[0088] FIG. 2 is a diagram showing the emission amount of brilliant
blue FCF as shown in Table 2. FIG. 2 shows that when the volume of
the powder to be added for the adhesive layer exceeds about 20%,
the emission amount of the brilliant blue is raised. Also, FIG. 2
shows that when the volume of the powder to be added for the
adhesive layer exceeds about 50%, the emission amount of the
brilliant blue reaches a peak.
[0089] As a result, when the volume of the powder to be added for
the adhesive layer exceeds about 20%, it seems that the spaces
(voids) between the powder is beginning to form in the adhesive
layer, and the brilliant blue inside the adhesive layer is
beginning to be released via the spaces. Also, when the volume of
the powder to be added for the adhesive layer exceeds about 50%, it
seems that the spaces (voids) between the powder are completely
formed in the adhesive layer. Thus, we think that the additional
powder makes no change in the release property of the brilliant
blue.
[0090] On the other hand, it was shown that when the volume of the
powder to be added exceeds about 110% of the volume of the adhesive
layer, the preparation becomes hard, and the adhesibility of the
preparation is deteriorated and it is unsuitable for a drug
formulation. Thus, it was demonstrated that the upper limit of the
amount of AEROSIL.RTM. to be added was about 110%.
[0091] Next, CEOLUS.RTM. (crystalline cellulose) having a larger
bulk density (i.e., having a smaller particle size) than
AEROSIL.RTM. was used as the powder, and the effects in various
volumes of the powder were evaluated. Specifically, the release
property of the brilliant blue from the adhesive layer was
evaluated using CEOLUS.RTM. as the powder according to the above
Table 2.
TABLE-US-00003 TABLE 3 B1 B2 B3 B4 B5 B6 B7 B8 Drug Solution:
Brilliant blue FCF 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016
Triethanolamine 10 9.88 9.76 9.39 9.15 8.78 9.53 8.17
Levulinate/Macrogol 400 Adhesive: Triethanolamine 10 9.88 9.76 9.39
9.15 8.78 9.53 8.17 Levulinate/Macrogol 400 Terpene Resin 38 37.54
37.07 35.68 34.75 33.36 32.43 31.03 SIS 20 19.76 19.51 18.78 18.29
17.56 17.07 16.33 Liquid Parffin 17 16.79 16.59 15.96 15.55 14.92
14.51 13.88 Butylhydroxytoluene 1 0.99 0.98 0.98 0.97 0.96 0.95
0.94 (Total weight of 96.0 94.8 93.7 90.1 87.8 84.3 81.9 78.4
adhesive layer) Filler (Powder): CEOLUS .RTM. (crystalline 0 1.17
2.35 5.87 8.21 11.73 14.08 17.6 cellulose) (Volume) (8.4) (16.8)
(41.9) (58.6) (83.8) (100.5) (125.7) Volume ratio of powder to 0
8.9 17.9 46.5 66.7 99.4 122.7 160.3 adhesive layer (%) Preparation
Form: good good good good good good good good Emission Amount 0.008
0.017 0.058 0.125 0.194 0.213 0.294 0.273 (Absorbance/Measurement
Wavelength 630 nm)
[Note]
[0092] The volume of CEOLUS.RTM. was calculated according to the
weight thereof/the bulk density thereof.
[0093] The "volume ratio of the powder to the adhesive layer" was
calculated according to the specific gravity of the adhesive layer
containing the drug solution defined as 1. FIG. 3 is a diagram
showing the emission amount of brilliant blue FCF as shown in the
above Table 3. FIG. 3 shows that when the volume of CEOLUS.RTM. to
be added for the adhesive layer exceeds about 20%, the emission
amount of brilliant blue is gradually raised. Also, FIG. 3 shows
that when the volume of CEOLUS.RTM. to be added exceeds about 120%
of the volume of the adhesive layer, the emission amount of
brilliant blue reaches a peak.
[0094] The difference between the amounts (volumes) of the powder
to be added as shown in the above Table 2 and Table 3 is shown to
be influenced by the difference between the bulk densities of
CEOLUS.RTM. and AEROSIL.RTM.. The bulk density of AEROSIL.RTM. is
smaller than that of CEOLUS.RTM., and thus the volume of the spaces
(voids) between the powder becomes larger. As a result,
AEROSIL.RTM. in small amount can make the spaces (voids) in the
adhesive layer.
[0095] In addition, the results of corn starch having a larger bulk
density than CEOLUS.RTM. are shown in Table 4 below and FIG. 4.
TABLE-US-00004 TABLE 4 C1 C2 C3 C4 C5 C6 C7 C8 Drug Solution:
Brilliant blue FCF 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016
Triethanolamine 10 9.58 9.17 7.92 7.09 5.84 5.01 3.77
Levulinate/Macrogol 400 Adhesive: Triethanolamine 10 9.58 9.17 7.92
7.09 5.84 5.01 3.77 Levulinate/Macrogol 400 Terpene Resin 38 36.42
34.84 30.10 26.94 22.21 19.05 14.31 SIS 20 19.17 18.34 15.84 14.18
11.69 10.03 7.53 Liquid Parffin 17 16.29 15.59 13.47 12.05 9.93
8.52 6.40 Butylhydroxytoluene 1 0.96 0.92 0.79 0.71 0.58 0.50 0.38
(Total weight of 96.0 92.0 88.0 76.1 68.1 56.1 48.1 36.2 adhesive
layer) Filler (Powder): corn starch 0 3.99 7.98 19.95 27.93 39.9
47.88 59.85 (Volume) (8.0) (16.0) (39.9) (55.9) (79.8) (95.8)
(119.7) Volume ratio of powder to 0 8.7 18.2 52.4 82.1 142.2 199.2
330.7 adhesive layer (%) Preparation Form: good good good good good
bad bad bad Amount of Emission 0.012 0.017 0.039 0.092 0.212 0.304
-- -- (Absorbance/Measurement Wavelength 630 nm)
[Note]
[0096] The volume of corn starch was calculated according to the
weight thereof/the bulk density thereof.
[0097] The "volume ratio of the powder to the adhesive layer" was
calculated according to the specific gravity of the adhesive layer
containing the drug solution defined as 1. --: not measured because
of bad preparations.
[0098] In order to make the spaces (voids) between the powder in
the adhesive layer by using corn starch having a large bulk
density, it was shown that it is necessary to add a large amount of
corn starch. However, when corn starch was excessively added, it
got difficult to formulate the drug, and thus the measurement of
the emission amount of the brilliant blue was discontinued. As a
result, the amount of corn starch to be added for maximizing the
emission amount of the brilliant blue could not be found.
[0099] Also, when the volume of the powder was calculated based on
the tap density of the powder in place of the bulk density of the
powder, the calculated volume became smaller. As a result, as shown
in FIG. 5 and FIG. 6, the ratio of [the volume of the powder] to
[the volume of the adhesive layer] became smaller, and the value in
the horizontal axis was decreased.
[0100] Thus, the spaces (voids) between the powder formed in the
adhesive layer are beginning to be formed by combining the powder
when the volume of the powder for the volume of the adhesive layer
(comprising a drug, etc.) is about 20% (calculated as the bulk
density of the powder) as shown in FIG. 2 and FIG. 3. In addition,
as shown in FIG. 5 and FIG. 6, the spaces (voids) between the
powder are completely formed when the volume of the powder for the
volume of the adhesive layer (comprising a drug, etc.) reached
about 60% (calculated as the tap density of the powder). This
result is summarized in the following inequality.
0.2 .times. ( calcutlated .times. .times. as .times. .times. the
.times. .times. bulk .times. .times. density .times. .times. of
.times. .times. the .times. .times. powder ) .ltoreq. ( the .times.
.times. volume .times. .times. of .times. .times. the .times.
.times. powder ) the .times. .times. volume .times. .times. of
.times. .times. the .times. .times. ahesive .times. .times. layer
.ltoreq. ##EQU00004##
0.6 (calculated as the tap density of the powder)
[0101] More specifically, when the powder is light anhydrous
silicic acid, the volume of the powder is preferably in the range
of 0.2 to 0.6 calculated as the bulk density thereof, and in the
range of 0.1 to 0.3 calculated as the tap density thereof.
Similarly, when the powder is crystalline cellulose, the volume of
the powder is preferably in the range of 0.2 to 1.2 calculated as
the bulk density thereof, and in the range of 0.1 to 0.6 calculated
as the tap density thereof. In addition, when the powder is corn
starch having a large bulk density, the volume of the powder is
preferably in the range of 0.2 to 0.7 calculated as the bulk
density thereof, and in the range of 0.1 to 0.4 calculated as the
tap density thereof.
[0102] Also, when the volume of the powder in the above inequality
is converted into the amount (weight) of the powder to be added,
the inequality is expressed as the following inequality.
0.2.times.(the weight of the adhesive layer).times.(the bulk
density of the powder).ltoreq.the amount of the powder to be
added.ltoreq.0.6.times.(the weight of the adhesive
layer).times.(the tap density of the powder).
[0103] The amount (weight) of the powder to be added can be
determined depending on the total weight of the adhesive layer
comprising a drug and a solvent. Thus, when the amount of the
ingredients such as the drug, the elastomer, and the tackifier in
the adhesive layer is maintained at a constant rate, the upper
limit and lower limit of the volume of the solvent available for
the adhesive layer can be determined. That is, the volume of the
solvent to be filled in the spaces (voids) between the powder can
be determined. When the volume of the solvent exceeds the upper
limit, the solvent exudes onto the surface of the adhesive layer.
As a result, the adhesibility of the tape preparation to the skin
is decreased, and the tape preparation is easily removed. Thus, the
upper limit of the volume of the solvent to be added depends on the
amount of the powder to be added.
Example 3
Weight-Composition of Powder and Spaces (Voids) Between Powder
Formed in Adhesive Layer
(1) Measurement of the Amount of Powder to be Added Required for
Forming Spaces (Voids):
[0104] The above results of Example 2 were converted to the
weight-composition of the powder to show the emission amount of
brilliant blue FCF graphically. The results are shown in FIGS. 7 to
9.
[0105] The rate of the spaces (voids) between the powder formed in
the adhesive layer was estimated based on the weight-composition
(w/w %) of the powder, and the estimated rate was shown to be
greatly affected by the bulk density (tap density) of the powder.
Specifically, it was demonstrated that light anhydrous silicic acid
having a large particle size and small bulk density of the powder
could form the spaces (voids) between the powder in the adhesive
layer in a small amount of light anhydrous silicic acid, whereas
crystalline cellulose and corn starch were required to further
increase the amount of the powder to be added, and the spaces
(voids) between the powder could not be sufficiently formed when
the weight-composition of the powder (w/w %) was not high. That is,
when the amount of powder having a large particle size such as
light anhydrous silicic acid was 1 w/w % or more, the spaces
(voids) were beginning to be formed, and when the amount was 2.5
w/w % or more, the spaces (voids) were sufficiently formed. Also,
it was shown that the amount of the powder to be added is
preferably 5 w/w % or less in view of the emission amount of the
brilliant blue.
[0106] In addition, when the amount of crystalline cellulose to be
added was 2.5 w/w % or more, the spaces (voids) between the powders
were beginning to be formed, and when the amount was 15 w/w %, the
spaces (voids) between the powders were sufficiently formed. Also,
it was shown that the amount of the powder to be added is
preferably 18 w/w % or less in view of the emission of the
brilliant blue.
[0107] Thus, it was demonstrated that the amount of the powder to
be added varies depending on the type of the powder to be added,
but the preferred amount of the powder is in the range of 1 to 18
w/w %. Also, the amount of light anhydrous silicic acid for forming
sufficient spaces (voids) is preferably 1 to 5 w/w %, and more
preferably 2.5 to 5 w/w %. Also, it was shown that the amount of
crystalline cellulose is preferably 2.5 to 18 w/w %, and more
preferably 5 to 15 w/w %.
(2) Measurement of the Amount of Solvent Required for Filling the
Spaces (Voids) Formed:
[0108] Maintaining the amount of the powder in the adhesive layer
(lipophilic adhesive plaster base) at a constant rate and using
various solvents, we studied how volume of each solvent is suitable
for exuding onto the surface of the adhesive layer without being
held in the spaces (voids) between the powder. When a solvent
exudes on the surface of the adhesive layer, the adhesibility of
the adhesive layer is decreased. Thus, the adhesibility of the
surface of the adhesive layer was evaluated to calculate the volume
of a solvent held in the spaces (voids) between the powder.
[0109] Each reagent was weighted according to the composition (w/w
%) in Table 5 below, terpene resin, styrene-isoprene-styrene
copolymer (SIS), diethyl sebacate, and liquid paraffin were
dissolved in toluene following the conventional solvent method, and
then macrogol 400 and light anhydrous silicic acid (AEROZIL.RTM.
200) were added thereto and mixed. Then, each mixture was applied
on the silicone-coated PET film and dried. After removal of the
toluene, the backing support was laminated to prepare each
preparation. The ball tack test was performed on the samples to
check whether Ball No. 4 was stopped.
[0110] The result is shown in Table 5 below.
TABLE-US-00005 TABLE 5 Formulation D1 D2 D3 Solvent Macrogol 400 34
41 45 (the volume of the solvent) (30.6) (36.9) (40.5) Adhesive
Terpene Resin 20 20 20 Layer Styrene-Isoprene-Styrene 15 15 15
Copolymer Liquid Paraffin 25 18 14 3 3 3 Powder Light Anhydrous
Silicic 3 3 3 Acid (AEROSIL .RTM. 200) (33.3) (33.3) (33.3) Total
100 100 100 Ratio of the solvent (the drug 0.9 1.1 1.2 solution) to
the volume of the powder (the amount of the powder/the tap density
of the powder) Ball Tack Test Result on Ball No. 4 Stopped Stopped
Not Stopped
[Note]
[0111] Macrogol 400: specific gravity of 1.11
[0112] The "Drug approval and licensing procedures in Japan"
describes that patch preparations have an excellent adhesibility
when stopping ball No. 4. As shown in the above Table 5, in the
ball tack test of Formulation No. D3, ball No. 4 was not stopped.
As a result, the adhesibility of the preparation was deteriorated.
The results show that when the solvent (macrogol) exceeds 1.2 times
the volume of the powder, the volume of the solvent used exceeds
the volume capacity of the spaces (voids) between the powder, and
the solvent exudes onto the surface of the adhesive layer.
[0113] According to the above results of the ball tack test, it was
demonstrated that the volume of the spaces (voids) between the
powder in the adhesive layer (lipophilic plaster base material) is
smaller than 1.2 times the volume of the powder, and the volume is
in the range of about 1.1 times the volume of the powder. As a
result, the upper limit of the amount of the solvent to be added
can be determined according to the following inequality.
the .times. .times. amount .times. .times. .times. of .times.
.times. the .times. .times. solvent .times. .times. to .times.
.times. be .times. .times. added ( the .times. .times. volume
.times. .times. of .times. .times. the .times. .times. solvent
.times. .times. to .times. .times. be .times. .times. added ) <
the .times. .times. amount .times. .times. of .times. .times. the
.times. .times. powder .times. .times. to .times. .times. be
.times. .times. added the .times. .times. top .times. .times.
density .times. .times. of .times. .times. the .times. .times.
powder .times. ( the .times. .times. volume .times. .times. of
.times. .times. the .times. .times. powder .times. .times. to
.times. .times. be .times. .times. added ) .times. 1.2
##EQU00005##
[0114] The solvent held in the spaces (voids) in the adhesive layer
is a solvent which is hard to dissolve in the adhesive layer
(lipophilic plaster base material) (i.e. a solvent which is less
compatible with the adhesive layer), and examples of the solvent
include an alcohol solvent (e.g. macrogol, propylene glycol, and
polyethylene glycol) and a protic solvent such as a fatty
acid-based ionic liquid and a fatty acid. On the other hand, an
ester solvent (e.g. diethyl sebacate and isopropyl myristate) is
more compatible with the adhesive layer (lipophilic plaster base
material), and thus it seems that the solvent is hard to be
retained in the spaces (voids) in the adhesive layer.
Example 4
Preparation of Tape Preparations Containing Light Anhydrous Silicic
Acid
[0115] Following the above results of Example 3, tape preparations
comprising the powder and agomelatine as an active ingredient were
prepared. Each reagent was weighed according to the composition
(w/w %) in Table 6 below to prepare the tape preparations by the
conventional solvent method. Table 6 also shows the results on the
permeability of agomelatine in the Franz cell method.
TABLE-US-00006 TABLE 6 Test No. A068 A103 A102 A092 A093 A097 A098
Agomelatine 1.0 1.0 1.0 1.0 1.0 1.0 1.0 (Powder) Light Anhydrous
Silicic Acid 1.0 2.0 3.0 3.5 4.0 5.0 (Organic Solvent) Isopropyl
Myristate 5.0 5.0 5.0 5.0 5.0 5.0 5.0 Propyl Carbonate 5.0 5.0 5.0
5.0 5.0 5.0 5.0 Polyethylene Glycol 5.0 5.0 5.0 5.0 5.0 5.0 5.0
N-Methyl-Pyrrolidone 2.8 2.8 2.8 2.8 2.8 2.8 2.8 (Fatty Acid-Based
Ionic Liquid) Triisopropanolamine Decanoate 0.9 0.9 0.9 0.9 0.9 0.9
0.9 Diisopropanolamine Oleate 1.3 1.3 1.3 1.3 1.3 1.3 1.3
Diisopropanolamine Isostearate 3.0 3.0 3.0 3.0 3.0 3.0 3.0
Triethanolamine Lactate 2.0 2.0 2.0 2.0 2.0 2.0 2.0 (Lipophilic
plaster base) Terpene Resin 38.0 38.0 37.0 36.0 36.0 36.5 36.0 SIS
18.0 17.0 17.0 17.0 17.0 16.0 16.0 Liquid Paraffin 17.0 17.0 17.0
17.0 16.5 16.5 16.0 (Antioxidant) Butylhydroxytoluene 1.0 1.0 1.0
1.0 1.0 1.0 1.0 Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Skin Permeation Amount 51.7 19.1 17.2 12.8 7.1 9.4 5.0
(.mu.g/cm.sup.2/6 hr)
[0116] As shown in the above Table 6, the release property of the
drug in the tape preparations containing light anhydrous silicic
acid had a tendency to be sustainedly released with increasing the
amount of the powder, and the cumulative skin permeation amount for
6 hours tended to be decreased. Then, we changed the powder from
light anhydrous silicic acid to crystalline cellulose to evaluate
the changes in the release property of the drug.
Example 5
Preparation of Tape Preparations Containing Crystalline
Cellulose
[0117] In the same manner as Example 4, tape preparations
containing crystalline cellulose as the powder were prepared. Each
reagent was weighed according to the composition (w/w %) in Table 7
below to prepare the tape preparations by the conventional solvent
method. Table 7 also shows the results about the permeability of
agomelatine in the Franz cell method.
TABLE-US-00007 TABLE 7 Test No. A068 A104 A105 A106 A107 A108
Agomelatine 1.0 1.0 1.0 1.0 1.0 1.0 (Powder) Crystalline Cellulose
1.0 2.0 3.0 4.0 5.0 (Organic Solvent) Isopropyl Myristate 5.0 5.0
5.0 5.0 5.0 5.0 Propyl Carbonate 5.0 5.0 5.0 5.0 5.0 5.0
Polyethylene Glycol 5.0 5.0 5.0 5.0 5.0 5.0 N-Methyl-Pyrrolidone
2.8 2.8 2.8 2.8 2.8 2.8 (Fatty Acid-Based Ionic Liquid)
Triisopropanolamine Decanoate 0.9 0.9 0.9 0.9 0.9 0.9
Diisopropanolamine Oleate 1.3 1.3 1.3 1.3 1.3 1.3
Diisopropanolamine Isostearate 3.0 3.0 3.0 3.0 3.0 3.0
Triethanolamine Lactate 2.0 2.0 2.0 2.0 2.0 2.0 (Lipophilic plaster
base) Terpene Resin 38.0 38.0 37.0 36.0 36.0 35.0 SIS 18.0 17.0
17.0 17.0 16.5 16.5 Liquid Paraffin 17.0 17.0 17.0 17.0 16.5 16.5
(Antioxidant) Butylhydroxytoluene 1.0 1.0 1.0 1.0 1.0 1.0 Total
100.0 100.0 100.0 100.0 100.0 100.0 Skin Permeation Amount 51.7 9.4
8.1 6.9 4.9 6.6 (.mu.g/cm.sup.2/6 hr)
[0118] As shown in the above Table 7, the drug in the tape
preparations containing crystalline cellulose was more sustainedly
released as compared to the drug in the tape preparation containing
light anhydrous silicic acid, and thus the cumulative skin
permeation amount for 6 hours was also more decreased.
[0119] The results suggest that the spaces (voids) between the
powder were not sufficiently formed in the adhesive layer due to
the small amount of crystalline cellulose to be added.
Specifically, it seemed that it is necessary to increase the bulk
density of the powder to suitably form the spaces (voids) between
the powder. Thus, we tried mixing some types of powders having
different particle sizes to improve the bulk density of the
powder.
[0120] It has been known that the volume of a mixture of powders
becomes the smallest when two types of powders having different
particle sizes are combined and the amount of powder having a
larger particle size to be added accounts for about 70% of the
total as shown in FIG. 10 (e.g. Kimio KAWAKITA et al., Bulletin of
the Faculty of Engineering, Hosei University 2, pages 47-53). Thus,
we studied about the combination of powders and the release
property of the drug based on the above composition.
Example 6
Preparation of Tape Preparation Containing Light Anhydrous Silicic
Acid and Crystalline Cellulose
[0121] Light anhydrous silicic acid (having a larger particle size)
and crystalline cellulose (having a smaller particle size) were
used as the powder having different particle sizes to prepare tape
preparations containing powder according to the composition (w/w %)
in Table 8 below. Table 8 also shows the results about the
permeability of agomelatine in the Franz cell method.
TABLE-US-00008 TABLE 8 Test No. A068 A082 A085 A088 Agomelatine 1.0
1.0 1.0 1.0 (Powder) Light Anhydrous Silicic Acid 3.0 2.0 1.0
Crystalline Cellulose 3.0 3.0 3.0 (Organic Solvent) Isopropyl
Myristate 5.0 5.0 5.0 5.0 Propyl Carbonate 5.0 4.0 4.0 4.5
Polyethylene Glycol 5.0 4.0 4.0 4.5 N-Methyl-Pyrrolidone 2.8 0.8
0.8 (Fatty Acid-Based Ionic Liquid) Triisopropanolamine Decanoate
0.9 0.9 0.9 0.9 Diisopropanolamine Oleate 1.3 1.3 1.3 1.3
Diisopropanolamine Isostearate 3.0 3.0 3.0 3.0 Triethanolamine
Lactate 2.0 2.0 2.0 2.0 (Lipophilic plaster base) Terpene Resin
38.0 36.0 35.0 35.0 SIS 18.0 17.0 17.0 17.0 Liquid Paraffin 17.0
17.8 19.0 19.0 Polybutene 1.0 1.0 1.0 (Antioxidant)
Butylhydroxytoluene 1.0 1.0 1.0 1.0 Total 100.0 100.0 100.0 100.0
Skin Permeation Amount (.mu.g/cm.sup.2/6 hr) 51.7 12.2 11.7
45.1
[0122] As shown in the above Table 8, when light anhydrous silicic
acid (having a larger particle size) and crystalline cellulose
(having a smaller particle size) were combined at a weight ratio of
1:3, the release property of the drug was unexpectedly and
drastically improved. The result was obtained when the amount of
light anhydrous silicic acid having a larger particle size was 25%.
FIG. 10 shows that the bulk density of the mixture can reach a peak
when the amount of light anhydrous silicic acid to be added is 70%.
However, the result was against the theory, which showed that 70 to
80% crystalline cellulose was necessary to suitably form the spaces
(voids) in the adhesive layer between the mixed powders. As
described above, it was found that it is preferable in case of
mixed powders to mix powder having a smaller particle size and
powder having a larger particle size at a ratio of 70 to 80:20 to
30 to effectively form the spaces (voids) in the adhesive layer. As
a result, the drug solution can be retained in the spaces (voids)
of the adhesive layer or the drug solution can be transferred to
the surface of the tape preparation via the spaces (voids), and
thus the drug solution or the drug can be released from the surface
of the tape preparation.
Example 7
[0123] Evaluation of the Release Property of Drug with Adhesive
Layer Containing Powder
[0124] The above results of Example 6 suggest that when two types
of powders (fillers) having different particle sizes are added into
the adhesive layer of the tape preparations, the drug solution
containing the drug (agomelatine) can be retained in the spaces
(voids) between the powder (filler) or between the powder and the
adhesive layer, and also the drug solution or the drug within the
adhesive layer can be effectively released onto the surface of the
adhesive layer via the spaces. As a result, it was shown that the
ratio of the residual drug in the adhesive layer was much lower
than that of the conventional tape preparations.
[0125] The tape preparations were prepared according to the
composition (w/w %) in Table 9 below, and the change in the drug
blood level in mice was measured to verify the above effect of the
present invention. Specifically, the tape preparations were
prepared according to the method of Example 2. The tape
preparations were used for evaluating the transdermal absorbability
of the drug in the Franz cell method of Test Example 1 and the
change in the drug blood level in mice. The results are shown in
Table 9 and FIG. 11.
TABLE-US-00009 TABLE 9 Test No. A260 A244 Agomelatine 2.0 2.0
(Powder) Crystalline Cellulose 3.0 Light Anhydrous Silicic Acid 1.0
(Organic Solvent) Dimethylisosorbide 1.2 1.2 Isopropyl Myristate
5.7 5.7 Propyl Carbonate 5.0 5.0 Polyethylene Glycol 7.5 7.5 (Fatty
Acid-Based Ionic Liquid) Triethanolamine Isostearate 2.5 2.5
Triethanolamine Lactate 1.5 1.5 (Lipophilic plaster base) SIS 17.2
16.5 Terpene Resin 35.0 33.7 Liquid Paraffin 19.5 17.5 (Other
Additives) Butylhydroxytoluene 1.0 1.0 Total 100.0 100.0 Cumulative
Skin Permeation Amount at 6 hours 6.2 36.5 (.mu.g/cm.sup.2)
[0126] As shown in Table 9, comparing the preparation of Test No.
A260 of having the adhesive layer with no powder with the
preparation of Test No. A244 having the adhesive layer containing
the powders, the transdermal absorbability of the drug in the tape
preparation containing the powders was dramatically improved.
Specifically, it was shown that the transdermal absorbability of
the drug in the preparation containing the powders was improved by
about 6 times as compared to that of the tape preparation with no
powder. This means that the release of the drug from the adhesive
layer was increased by about 6 times. Thus, it seems that the drug
was easily released from the surface of the adhesive layer via the
spaces (voids) formed by the addition of the powders to the
adhesive layer.
[0127] In addition, it has been found that when in vivo drug blood
level in mice was evaluated according to Test Example 1, the
preparation containing the powders (Test No. A244) sustainedly
released the drug as shown in FIG. 11.
[0128] The preparation of Example 6 with no powder (Test No. A068)
was shown to have the excellent transdermal absorbability of the
drug. As shown in FIG. 12, however, the change in the drug blood
level was evaluated with a rat treated with (Test No. A068), in
which the drug blood level reached a peak 2 hours after the
preparation was applied to the skin, and then was rapidly
decreased. The change in the drug blood level as shown in FIG. 12
is greatly different from that of the present invention as shown in
FIG. 11.
[0129] FIG. 13 shows that the change in the drug blood level of the
present invention as shown in FIG. 11 is composed of biphasic
behaviors of a dashed part showing immediate-release property of
the drug and a dotted part showing the slow-release property of the
drug. As shown in FIG. 14, these behaviors are derived from the
presence of the region forming the spaces (voids) in which the
powders are collectively combined in the adhesive layer and the
region in which the powder is relatively empty in the adhesive
layer, that is, the region in which the spaces (voids) are not
sufficiently formed.
[0130] As described above, the release property of the drug from
the adhesive layer containing the powder of the present invention
is composed of the biphasic properties (immediate-release and
sustained-release properties) as shown in FIG. 13. Thus, it has
been found that it is possible to make any one selected from the
immediate-release and sustained-release behaviors of the drug
better by arranging the amount of the powders to be added and the
combination of the powders.
Example 9
[0131] Evaluation of the Utilization Rate of Drug in Tape
Preparations with Adhesive Layer Containing Powder
(1) Tape Preparation Comprising Agomelatine as Active
Ingredient
[0132] In the same manner as Example 2, each reagent was weighed
according to the composition (part by weight) in Table 10 below to
prepare the tape preparations comprising agomelatine as a drug.
[0133] Specifically, agomelatine was mixed with the fatty
acid-based ionic liquids to prepare a drug solution. Following the
conventional solvent method using toluene as the solvent, the
organic solvents, the antioxidants, the lipophilic plaster base
materials, and the drug solution were mixed. Next, crystalline
cellulose and light anhydrous silicic acid were added thereto and
mixed, and then the mixture was applied on the silicone-coated PET
film and dried. After removal of the toluene, the backing support
was laminated to prepare the preparation.
[0134] Following Test Example 1 below, the in vitro skin
permeability test was performed with the prepared patch
preparations comprising agomelatine. The results are also shown in
Table 10.
TABLE-US-00010 TABLE 10 Test No. A223 A197 Agomelatine 1.0 1.0
(Powder) Light Anhydrous Silicic Acid 1.0 Crystalline Cellulose 3.0
(Organic Solvent) Isopropyl Myristate 3.8 3.8 Propyl Carbonate 6.0
5.0 Polyethylene Glycol 6.0 5.0 (Fatty Acid-Based Ionic Liquid)
Triethanolamine Isostearate 2.5 2.5 Triethanolamine Lactate 1.5 1.5
(Lipophilic plaster base) Terpene Resin 36.3 35.3
Styrene-Isoprene-Styrene Block Copolymer 20.0 19.0 Liquid Paraffin
19.5 19.5 (Other Additives) Kollidon .RTM. K90 0.5 0.5 Oleic Acid
1.9 1.9 Butylhydroxytoluene 1.0 1.0 Total Skin Permeation Amount
(.mu.g/cm.sup.2/6 hr) 9.1 26.7
[0135] As shown in Test Nos. A197 and A223 of the above Table 10,
the transdermal absorbability of agomelatine in the tape
preparation containing the powders was improved by about 3
times.
[0136] In addition, the measured ratio of the residual drug in the
preparation of Test No. A197 was about 40%. As a result, it was
found that the ratio of trandermally-absorbed agomelatine was about
60%. Thus, it was shown that the tape preparation of the present
invention containing powder produced the excellent effect that the
drug was transdermally absorbed at a high utilization rate.
(2) Tape Preparations Comprising Oxycodone as Active Ingredient
[0137] In the same manner as Example 2, each reagent was weighed
according to the composition (part by weight) in Table 11 below to
prepare the tape preparations comprising oxycodone as a drug.
[0138] Specifically, oxycodone hydrochloride hydrate was mixed with
the fatty acid-based ionic liquids to prepare a drug solution.
Following the conventional solvent method using toluene as the
solvent, organic solvents, antioxidants, lipophilic plaster base
materials, light anhydrous silicic acid, and the drug solution were
mixed, and then each mixture was applied on the silicone-coated PET
film and dried. After removal of the toluene, the backing support
was laminated to prepare the preparations. Following Test Example 1
below, the in vitro skin permeability test was performed with the
prepared patch preparations comprising oxycodone. The results are
also shown in Table 11.
TABLE-US-00011 TABLE 11 Test No. K886 K884 N423 Oxycodone
Hydrochloride Hydrate 2.31 2.31 2.31 (Powder) Light Anhydrous
Silicic Acid 4.0 4.0 (Organic Solvent) Isopropyl Myristate 5.0 5.0
5.0 Propyl Carbonate 10.0 10.0 10.0 Propylene Glycol 14.5 14.5
Dipropylene Glycol 5.0 Oleyl Alcohol 5.0 Diethyl Sebacate 7.0
(Fatty Acid-Based Ionic Liquid + Fatty Acid) Capric Acid 0.98 0.98
0.98 Isostearic Acid 6.0 6.0 6.0 Myristic Acid 0.4 0.4 0.4 Oleic
Acid 0.8 0.8 0.8 Diisopropanolamine 1.65 1.65 1.98 (Lipophilic
plaster base) Terpene Resin 27.0 27.0 30.0 Plastibase .RTM. 5.0 5.0
Styrene-Isoprene-Styrene 15.0 15.0 16.0 Block Copolymer Liquid
Paraffin 3.27 3.27 4.54 (Other Additives) Butylhydroxytoluene 1.0
1.0 1.0 Ascorbic Acid 0.1 0.1 0.1 Sodium Lactate 0.9 Total 96.0
100.0 100.0 Skin Permeation Amount 122 160 89 (.mu.g/cm.sup.2/6 hr)
Adhesibility Test (Ball 2 37 -- Tack Test) Adhesion Time of Ball
(difficulty (Stopping) No. 4 (sec) in stopping) Ratio of the
residual -- 15 19 drug (%) [NOTE] --: Not measured
[0139] As shown in the above Table 11, the tape preparation with no
powder (Test No. K886) contains a large volume of the solvent, and
thus the solvent exudes onto the surface of the adhesive layer. As
a result, the adhesibility of the tape preparation is not strong.
On the other hand, the preparation containing the powder (Test No.
K884) which has the same composition as the tape preparation with
no powder (Test No. K886) was improved in the transdermal
absorbability of the drug by 1.3 times. And, the adhesibility of
the tape preparation was also increased. In addition, the ratio of
the residual drug in the tape preparation containing the powder was
about 15%, and thus it is presumed that the ratio of the
transdermally-absorbed drug was about 85%.
[0140] As described above, the composition for the tape preparation
containing the powder was improved in the transdermal absorbability
of the drug, and the utilization rate of the drug was dramatically
improved. The utilization rate of the drug in conventional tape
preparations is generally about 10%, whereas the utilization rate
of the drug in the tape preparations containing the powder (Test
No. K884 and Test No. N423) was more than 80%, said high
utilization rate of the drug was an excellent result. In addition,
it was shown that the adhesibility of the tape preparations
containing the powder was also effectively maintained by comparison
of the preparations of Test No. K886 and Test No. 884.
[0141] The preparation of Test No. N423 is a tape preparation in
which the amount of the powder to be added is decreased and the
relative amount of the ester solvent is increased as compared to
the preparation of Test No. K884. On the other hand, the skin
permeation amount of the preparation of Test No. N423 in Table 11
was decreased by about half as compared to that of the preparation
of Test No. K884, but the ratio of the residual drug was 19%, i.e.,
the ratio of the residual drug showed little change. The drug blood
level was measured according to Test Example 2. The result showed
that the drug blood level reached a peak about 3 hours after the
preparation was applied to the skin as shown in Table 12 below and
FIG. 15.
TABLE-US-00012 TABLE 12 0 hr 3 hr 8 hr 24 hr Drug Blood level
(ng/mL) 0 54.5 16.5 0 Ratio of the residual drug (%) 19
[0142] The volume of the powder in the preparation of Test No. N423
(33.3 ml in 100 g of the preparation) is thought to be close to
that of the solvent which is less compatible with the powder such
as an alcohol solvent and a fatty acid-based ionic liquid. From the
result, we think that oxycodone can be easily released as shown in
Table 12 and FIG. 15. Thus, the image in FIG. 14 is supported by
the change in the drug blood level.
Test Example 1
In Vitro Skin Permeability Test
[0143] The tests for evaluating the transdermal absorbability of
agomelatine in the tape preparations of Examples 4 to 9 were
performed using a Franz diffusion cell (the permeable area: 1
cm.sup.2, the volume of the receptor solution: 8 mL) at a test
temperature of 32.degree. C. as follows:
(1) Rat's skin: skin isolated from the abdomen of a 5-week old
Wistar rat (male) (2) Receptor solution: physiological saline+10%
ethanol (3) Concentration measurement of the permeable drug:
HPLC
[0144] The commercially available rat's abdominal frozen skin
(5-week old Wistar rat) was mounted in a vertical diffusion cell
(the effective diffusion area: 1 cm.sup.2). Each sample in Tables 5
to 11 was applied to the stratum corneum side, and physiological
saline+10% ethanol was applied to the dermic layer side. The skin
permeability of the drug was measured by HPLC to determine the
cumulative permeation amount of the drug for 2 hours and 4 hours.
As a result, the transdermal absorbability of agomelatine as shown
in
[0145] Tables 5 to 11 could be evaluated.
Test Example 2
Test for Evaluating In Vivo Drug Blood Levels in Rats
(1) Laboratory Animal:
[0146] 5-week old Wistar rat (male)
(2) Test Method:
[0147] The test sample was prepared by cutting the preparation
sample of Test No. A068 (agomelatine, 133 .mu.g/cm.sup.2) into 2
cm.times.2 cm as an adhesive plaster type patch preparation. One
group was composed of 6 rats. The hairs around the administration
site (from the back to the lateral region) on the rats were removed
with an electric hair clipper [THRIVE, Model 5500 (0.05 mm), Daito
Electric Machine Industry Co., Ltd.], and then the whiskers on the
rats was removed with an electric shaver (Cleancut, Seiko S-Yard
Co. Ltd.). To each rat were attached 3 sheets of the preparation
samples, and blood was collected from the rats 1 hour, 2 hours, 4
hours, 8 hours, 12 hours, and 24 hours after administration.
[0148] To glass tubes were added 200 .mu.l of the blood plasma
collected from the rats, and 200 .mu.l of physiological saline was
added thereto and the plasma was homogenized. Then, 500 .mu.l of
diethyl ether was added thereto, and each mixture was stirred with
a vortex mixer, and then centrifuged for minutes to collect the
ether layer. Similar ether extraction method was performed on the
remaining water layer 3 times in total. The extracted ether layer
was combined, and the solvent in the combined ether layer was
distilled away under high purity nitrogen stream. After evaporation
of the ether, 200 .mu.l of water was added to the resulting dried
residues to dissolve the residues. Then, each solution was passed
through a 0.45 .mu.m filter for filtration, and 10 .mu.l of the
filtrate was analyzed by HPLC.
[0149] Also, the preparation sample of Test No. A244 (agomelatine,
266 .mu.g/cm.sup.2) was prepared to measure the drug blood levels
in the rats in the same manner as the above.
[0150] As with the above, using oxycodone, the drug blood levels in
the rats were measured (oxycodone hydrochloride, 286
.mu.g/cm.sup.2). The preparation of Test No. N423 was used as the
sample.
(3) Results
[0151] FIG. 11 and FIG. 12 show the changes in the level of
agomelatine in the plasma obtained from the above analyzed results.
In addition, FIG. 15 shows the change in the level of oxycodone in
the plasma.
INDUSTRIAL APPLICABILITY
[0152] The non-aqueous tape preparation of the present invention
comprising powder ingredient is characterized in that the powder
ingredient makes spaces in a lipophilic adhesive layer, a drug
solution is retained in the spaces, and then a drug is gradually
released. Also, the tape preparation has an improved adhesibility
since a solvent is not retained onto the surface of the adhesive
layer of the tape preparation. In addition, both of the
adhesibility of the tape preparation and the release property of
the drug solution, which are conflicting factors in normal tape
preparations, can be improved in the present invention, and thus
the transdermal absorbability of the drug can also be improved.
Thus, the tape preparation of the present invention has an
excellent adhesibility to the skin and further an improved
transdermal absorbability of the drug, based on the above effects.
Also, the tape preparation can sustainedly release the drug since
the drug solution is gradually released from the spaces between the
powder. As a result, the non-aqueous tape preparation of the
present invention has made it possible to expand the use to new
applications in the tape preparation comprising a drug solution in
which a drug is dissolved in an organic solvent with high polarity
or the non-aqueous tape preparation comprising an ionic liquid, and
thus has also made it possible to expand the possibility of
treating diseases with the tape preparation.
* * * * *